[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Bioventix Plc LSE:BVXP London Ordinary Share GB00B4QVDF07 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  125.00 3.25% 3,975.00 3,900.00 4,050.00 3,975.00 3,950.00 3,950.00 1,791 11:14:36
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 10.3 8.2 139.4 28.5 207

Bioventix Share Discussion Threads

Showing 1026 to 1049 of 1350 messages
Chat Pages: Latest  42  41  40  39  38  37  36  35  34  33  32  31  Older
DateSubjectAuthorDiscuss
02/8/2019
17:09
An extract from a front page article in The Times today. "A simple blood test that can detect the onset of Alzheimer's has been developed by scientists in a breakthrough for combating the disease. The test could speed up diagnosis in GP surgeries and boost the development of drugs to tackle the condition. Researchers showed that the test had more than 90% accuracy in spotting toxic proteins in the brain that can be an early indication of the disease." "...the procedure could be in use in little more than a year as a means of recruiting people en masse for clinical trails." Details of the blood test were published in the journal 'Neurology'. No specific mention of BVXP in The Times article, although BVXP has been collaborating with Pre Diagnostics AS for a blood-based beta amyloid Alzheimer’s diagnostic test.
robinnicolson
02/8/2019
14:58
Understood
red5
02/8/2019
13:55
Red5, I’m not accusing you of ramping, I understand your argument. Just saying it wouldn’t influence my decision to buy or hold any share including this one.
chippyfriday
02/8/2019
13:07
You could just drop 10/11/12/13, they are ancient history now.
stepone68
02/8/2019
13:06
gnnmartin - I'll have a look at what I can do with the elongated table when I have some time. Either two tables as you suggest or now move to discrete financial years, not half years. SM
strollingmolby
02/8/2019
12:33
Nobody is ramping its a discussion on what benefits Brexit may or not bring to the markets and how and how to tie them down to industry sectors. For me I see the low pound being a tempting target for our cousins abroad.
red5
02/8/2019
12:08
I have an investing rule to never buy or hold a share because of takeover hopes alone. Buy or hold for other reasons but not for that (the last refuge of the ramper?). But not suggesting or implying that anyone here is ramping.
chippyfriday
02/8/2019
10:27
nice move up anybody know why
red5
01/8/2019
19:14
So Which sectors might be vulnerable to American companies
red5
01/8/2019
18:38
I think that makes for potent mix.
red5
01/8/2019
18:29
Have no idea but would definitely expect M&A activity generally on a hard brexit - perfect storm of easy capital and distressed currency
williamcooper104
01/8/2019
18:13
Listen moron with the pound being so cheap our stocks look cheaper plus if we come out of the European Union/ market restrictions on European stocks being owned by non European companies are lifted the US I have heard view our stocks cheap at the moment so wanted everyone’s opinion.
red5
01/8/2019
17:44
Are there any boards where you haven't posted that?
trident5
01/8/2019
17:13
is bioventix ripe for takeover?
red5
30/7/2019
09:54
from W-XP, W-7 to W-10 I have the same problem - Screen 17" x 17"
piedro
30/7/2019
09:21
i have a mac running on v 10.13.6 and dont have that problem. perhaps you could try updating the os.
alter ego
29/7/2019
12:51
Strolling M. Any chance you could rework the header? The table headed '6 month segments' forces a wide page width, on my machine anyhow (OSX 10.10.5 + Safari). If you broke it into two tables, that would cure the problem.
gnnmartin
29/7/2019
09:38
The author of the cMyC research thinks it may best be used in a combo panel with troponin: Https://twitter.com/tomkaier/status/1155368714059026433
gsbmba99
29/7/2019
09:29
Https://www.ahajournals.org/doi/10.1161/JAHA.119.013152 New cMyC research using the old assay developed for Erenna platform. "In patients undergoing blood draws very early after symptom onset, cMyC demonstrates improved diagnostic discrimination of AMI and could significantly improve the early triage of patients with suspected AMI." Also of note: "We have recently contracted a POCT diagnostics device manufacturer to migrate cMyC onto their platform." BVXP is working to develop a cMyC antibody.
gsbmba99
17/7/2019
22:52
£35 is the SMA(200) bamboo2 it doesn't seem to want to go much below that. I'm juggling ABC into BVXP, too. So, I would be pleased to see some strength in ABC matched to some weakness in BVXP. apad 😇
apad
17/7/2019
22:33
Apad, There is a small H&S that may get a lower entry point. Currently unconfirmed, it needs an eod close below 3650 to confirm a tp of approx 3366 Historical support approx 3550 provides an obstacle to this tp.
bamboo2
17/7/2019
21:26
Also, a longer time of observation or more tests uses very expensive beds and physician time. There is a long history of the uncertainties and variability associated with diagnosis. There is also a long history of different forms of practice and the variability of decisions by doctors - referred to in the reference by addressing the need for a concerted approach by the different practitioners involved - it was the same issue in the 1950s. Thanks again for your references gsbmba99. BVXP seems to be flirting with the £37 level after recent strength. I am rather hoping for weakness to increase. apad
apad
17/7/2019
19:32
I appreciate the response. It's a fair point that 50% of something can still be very worthwhile!
spann_703
17/7/2019
19:04
It depends on the reference population. In this case, being able to send home safely nearly 50% of people presenting at A&E with chest pain and suspicion of a heart attack after a single blood test and an ECG is very good. The other 50% either warrant further observation (~38%) or are having a heart attack (~12%). Also bear in mind that missed heart attack is number one source of medical malpractice claims in US. Other protocols have higher rule out percentages but require another 1-4 hours to run a second blood test. Chest pain is an extremely common (first/second) cause of A&E presentation, is very non-specific but has consequences ranging from trivial to lethal.
gsbmba99
Chat Pages: Latest  42  41  40  39  38  37  36  35  34  33  32  31  Older
ADVFN Advertorial
Your Recent History
LSE
BVXP
Bioventix
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210922 13:33:19